Silihan lan utang jangka dawa perusahaan: RAPT Therapeutics, Inc. (RAPT)

RAPT Therapeutics, Inc. (RAPT) develops oral therapies to combat severe inflammatory pathologies while awaiting FDA approval and data on turalinon. In partnership with oncology centers, the company is studying the characteristics of tumor environments. This chart reflects the current market value of long-term liabilities on GURU.Markets at 0.00. However, the absence of commercial products results in a steady cash burn without operating profit.

For RAPT Therapeutics, Inc. (RAPT), long-term debt serves as an indicator of financial stability during a period of strategic pipeline reorientation. This metric aggregates obligations with maturities exceeding one year, allowing investors to filter out short-term fluctuations and identify a sustainable trend in credit load. The dynamics are calculated daily, transforming static quarterly data into a continuous monitoring stream of borrowed capital. This enables investors to assess the liquidity reserve available to fund the company's most promising molecules.